Immunolesion-induced loss of cholinergic projection neurones promotes β-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice

Neuropathology and Applied Neurobiology

Volumn 40, Issue 2, 2014, Pages 106-120

  Hartig W ^a   Saul, A ^b   Kacza, J ^a   Grosche, J ^a   Goldhammer, S ^a   Michalski, D ^a   Wirths, O ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Alzheimer's disease; Animal model; Basal forebrain; Cholinotoxin; Hippocampus; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINE ACETYLTRANSFERASE; FLUORESCENT DYE; IMMUNOTOXIN; NEUROTROPHIN RECEPTOR P75; PROTEIN; PROTEIN C99; PROTEIN P75; SAPORIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGE; ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CHEMICAL ANALYSIS; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FOREBRAIN; GLIA; GLIOSIS; HIPPOCAMPUS; HISTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALZHEIMER'S DISEASE; ANIMAL MODEL; BASAL FOREBRAIN; CHOLINOTOXIN; HIPPOCAMPUS; TAU;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANIMALS; CHOLINERGIC NEURONS; DISEASE MODELS, ANIMAL; GLIOSIS; HIPPOCAMPUS; IMMUNOTOXINS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; RIBOSOME INACTIVATING PROTEINS, TYPE 1; TAU PROTEINS;

EID: 84887514028     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12050     Document Type: Article

References (83)

1. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (Berl) 2008; 115: 5-38
2. Groschus JM. Do amyloid oligomers act as traps for misfolded proteins? A hypothesis. Amyloid 2008; 15: 160-165
3. Walker LC, LeVine H III. Corruption and spread of pathogenic proteins in neurodegenerative diseases. J Biol Chem 2012; 287: 33109-33115
4. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991; 12: 383-388
5. Selkoe DJ. Alzheimer's disease: genes, proteins and therapy. Physiol Rev 2001; 8: 741-766
6. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-1159
7. Davies P, Maloney J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 308: 1403
8. Whitehouse PJ, Price DL, Clark AW, Coyle JT, De Long MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-126
9. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol (Berl) 1983; 61: 101-108
10. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495-529
11. Mesulam MM. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem 2004; 11: 43-49
12. Götz J, Streffer J, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 2004; 9: 664-683
13. LaFerla F, Oddo S. Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol Med 2005; 11: 170-176
14. Small SA, Duff K. Linking Aβ and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008; 60: 534-542
15. Zahs KR, Ashe KH. 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci 2010; 33: 381-389
16. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease: intracellular Aβ and synaptic dysfunction. Neuron 2003; 39: 409-421
17. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003; 24: 1063-1070
18. Mastrangelo MA, Bowers WJ. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci 2008; 9: 81
19. Oh KJ, Perez SE, Lagalwar S, Vana L, Binder L, Mufson EJ. Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis. Int J Alzheimers Dis 2010; 2010: pii 780102, doi: 10.4061/2010/780102
20. Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004; 55: 815-828
21. Girão da Cruz MT, Jordão J, Dasilva KA, Ayala-Grosso CA, Ypsilanti A, Weng YQ, LaFerla FM, McLaurin J, Aubert I. Early increases in soluble amyloid-β levels coincide with cholinergic degeneration in 3xTg-AD mice. J Alzheimers Dis 2012; 32: 267-272
22. Perez SE, He B, Muhammad N, Oh KJ, Fahnestock M, Ikonomovic MD, Mufson EJ. Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol Dis 2011; 41: 338-352
23. Girão da Cruz M, Ypsilanti AR, Oddo S, LaFerla FM, McLaurin M, Aubert I. Cholinergic degeneration in the triple transgenic mouse model. 2006; Poster 375.18. 2006 Neuroscience Meeting Planner. Atlanta, GA, USA: Society for Neuroscience
24. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease - interrelationship with β-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005; 30: 895-908
25. Wiley RG, Oeltmann TN, Lappi DA. Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor. Brain Res 1991; 562: 149-153
26. Wiley RG. Neural lesioning with ribosome-inactivating proteins: suicide transport and immunolesioning. Trends Neurosci 1992; 15: 285-290
27. Witter MP, Amaral DG. Hippocampal formation. In The Rat Nervous System 3rd edn. Ed G Paxinos. San Diego, CA: Elsevier, 2004; 635-704
28. Freund TF, Buzsáki G. Interneurons of the hippocampus. Hippocampus 1996; 6: 347-470
29. Franklin K, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press, 1997
30. Hahn S, Brüning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, Weggen S. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. J Neurochem 2011; 116: 385-395
31. Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 1997; 48: 128-132
32. Weaver CL, Espinoza M, Kress P, Davies P. Conformational change is one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 2000; 21: 719-727
33. Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR, Weidensteiner C, von Kienlin M, Ozmen L. Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice. Neurobiol Dis 2010; 37: 294-306
34. Härtig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J. Concomitant detection of β-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple-transgenic mice. J Chem Neuroanat 2010; 40: 82-92
35. Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 1999; 47: 719-730
36. Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, Lee VM. Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration. J Neurosci 2011; 31: 7691-7699
37. Roßner S. Cholinergic immunolesions by 192IgG-saporin - a useful tool to simulate pathogenic aspects of Alzheimer's disease. Int J Dev Neurosci 1997; 15: 835-850
38. Berger-Sweeney J, Stearns NA, Murg SL, Floerke-Nashner LR, Lappi DA, Baxter MG. Selective immunolesions of cholinergic neurons in mice: effects on neuroanatomy, neurochemistry, and behavior. J Neurosci 2001; 21: 8164-8173
39. Moreau PH, Cosquer B, Jeltsch H, Cassel JC, Mathis C. Neuroanatomical and behavioral effects of a novel version of the cholinergic immunotoxin mu p75-saporin in mice. Hippocampus 2008; 18: 610-622
40. Wallace W, Haroutunian V. Using the subcortically lesioned rat cortex to understand the physiological role of amyloid precursor protein. Behav Brain Res 1993; 57: 199-206
41. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002; 68: 209-245
42. Härtig W, Bauer A, Brauer K, Grosche J, Hortobágyi T, Penke B, Schliebs R, Harkany T. Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions? Rev Neurosci 2002; 13: 95-165
43. Pákáski M, Kálmán J. Interaction between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int 2008; 53: 103-111
44. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011; 221: 555-563
45. Contestabile A, Ciani E, Contestabile A. The place of choline acetyltransferase activity measurement in the 'cholinergic hypothesis' of neurodegenerative diseases. Neurochem Res 2008; 33: 318-327
46. Loreth D, Ozmen L, Revel FG, Knoflach F, Wetzel P, Frotscher M, Metzger F, Kretz O. Selective degeneration of septal and hippocampal GABAergic neurons in a mouse model of amyloidosis and tauopathy. Neurobiol Dis 2012; 47: 1-12
47. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 2008; 8: 1703-1718
48. Hernandez D, Sugaya K, Qu T, McGowan E, Duff K, McKinney M. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport 2001; 12: 1377-1384
49. Boncristiano S, Calhoun ME, Kelly PH, Pfeifer M, Bondolfi L, Stalder M, Phinney AL, Abramowski D, Sturchler-Pierrat C, Enz A, Sommer B, Staufenbiel M, Jucker M. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 2002; 22: 3234-3243
50. German DC, Yazdani U, Speciale SG, Pasbakhsh P, Games D, Liang CL. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J Comp Neurol 2003; 462: 371-381
51. SW mice. Brain Res 2003; 977: 16-22
52. NTR cholinergic basal forebrain septohippocampal pathway. Exp Neurol 2001; 170: 227-243
53. Freund TF, Antal M. GABA-containing neurons in the septum control inhibitory interneurons in the hippocampus. Nature 1988; 336: 170-173
54. Gil-Bea FJ, Gerenu G, Aisa B, Kirazov LP, Schliebs R, Ramírez MJ. Cholinergic denervation exacerbates amyloid pathology and induces hippocampal atrophy in Tg2576 mice. Neurobiol Dis 2012; 48: 439-446
55. Liskowsky W, Schliebs R. Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 2006; 24: 149-156
56. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42: 631-639
57. Lorenzo A, Yankner BA. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994; 91: 12243-12247
58. D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol 2003; 62: 137-145
59. Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004; 7: 1181-1183
60. Dahlgren KN, Manelli A, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-32053
61. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006; 440: 352-357
62. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012; 15: 349-357
63. 1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci 2012; 32: 7852-7861
64. 2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010; 30: 11938-11950
65. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007; 170: 1669-1675
66. Sergeant N, Delacourte A, Buée L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 2005; 1739: 179-197
67. Hernández F, Avila J. Tauopathies. Cell Mol Life Sci 2007; 64: 2219-2233
68. Götz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008; 9: 532-544
69. Frank S, Clavaguera F, Tolnay M. Tauopathy models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115: 39-53
70. Howlett DR, Richardson JC. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? Histol Histopathol 2009; 24: 83-100
71. Kokjohn TA, Roher AE. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 2009; 5: 340-347
72. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8: 663-672
73. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005; 11: 164-169
74. Delacourte A. General and dramatic glial reaction in Alzheimer brains. Neurology 1990; 40: 33-37
75. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989; 24: 173-182
76. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10: 1387-1394
77. Wegiel J, Wang KC, Tarnawski M, Lach B. Microglia cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plaque degradation. Acta Neuropathol (Berl) 2000; 100: 356-364
78. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 2008; 28: 4283-4292
79. Grathwohl SA, Kälin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M. Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia. Nat Neurosci 2009; 12: 1358-1360
80. Streit WJ. Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res Brain Res Rev 2005; 48: 234-239
81. Giacobini E, Becker RE. One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J Alzheimers Dis 2007; 12: 37-52
82. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 2012; 62: 1099-1110
83. Apelt J, Schliebs R. β-amyloid-induced glial expression of both pro- and anti- inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 2001; 894: 21-30